RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site

Abstract excerpt

RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Protein Kinase Regulation and GTPase Signaling
• Share to RNA and protein synthesis mechanisms